Search academic texts

Information × Registration Number 0208U004310, 0105U001227 , R & D reports Title To study safety and efficacy of long-term use of various melatonin doses in elderly people with a reduced melatonin-producing function of the pineal gland popup.stage_title Head Korkushko Oleg Vasilievich, Доктор медичних наук Registration Date 14-03-2008 Organization State Institute of Gerontology of the Ukrainian Academy of Medical Sciences popup.description2 Purpose: To elucidate safety and efficacy of long-term use of various melatonin doses in the elderly with functional pineal gland insufficiency. Subjects: Fifty-seven elderly subjects, age range 60 to 74 years, with a reduced pineal gland melatonin-producing function who underwent treatment with melatonin in the dose of 3 mg (n=15), 1.5 mg (n=15) and 0.5 mg (n=12) given daily in the evening during 6 months. Fifteen persons received the placebo. Methods: Immune-enzymic assessment of urine 6-hydroxy-melatonin sulphate concentration, laser doppler flowmetry, viscosity and aggregate measurements, prescribed psychoemotional test, bicycle ergometry, neuropsychological and biochemical methods, and electroencephalography. Results: It has been found that intake of 0.5 mg melatonin at 9 p.m. is sufficient for compensation of functional pineal gland insufficiency in elderly. In long-term melatonin intake there have been sleep and anxiety improvements. Melatonin efficacy in the doses from 0.5 mg to 3 mg was identical in sleep disorders and surpassed that of the placebo. The outcome of functional pineal gland insufficiency compensation has been the normalization or improvement of a number of indices and organism's functions, in particular: arterial blood pressure, sleep, vascular-motor function of the endothelium, stress reactivity of the cardiovascular system, blood viscosity, thymic gland endocrine function, blood cholesterol concentration, mental ability and short-term memory. The 6-month-long use of melatonin in 0.5-3 mg doses by the elderly has been found safe. Drug intake discontinuation did not cause suppression of the epiphyseal melatonin-producing function. Areas of application of the results obtained: preventive and clinical medicine, gerontology and geriatrics. Forms of introduction: patent, information letter, articles and presentations. Product Description popup.authors popup.nrat_date 2020-04-02 Close